Infective endocarditis explained

Infective endocarditis
Synonyms:Bacterial endocarditis
Field:Cardiology, infectious disease
Symptoms:Fever, small areas of bleeding into the skin, heart murmur, feeling tired, low red blood cells
Complications:Valvular insufficiency, heart failure, stroke, kidney failure Blood clot in a lung artery (pulmonary embolism)[1] Enlarged and painful spleen, kidney damage, damage to the distal extremities such as fingers and toes.[2]
Causes:Bacterial infection, fungal infection
Risks:Valvular heart disease including rheumatic disease, congenital heart disease,[3] artificial valves, hemodialysis, intravenous drug use, electronic pacemakers[4]
Diagnosis:Based on symptoms, blood cultures, ultrasound
Treatment:Antibiotics, heart surgery
Prognosis:25% risk of death
Frequency:5 per 100,000 per year

Infective endocarditis is an infection of the inner surface of the heart, usually the valves. Signs and symptoms may include fever, small areas of bleeding into the skin, heart murmur, feeling tired, and low red blood cell count.[5] [6] Complications may include backward blood flow in the heart, heart failure – the heart struggling to pump a sufficient amount of blood to meet the body's needs, abnormal electrical conduction in the heart, stroke, and kidney failure.[5] [7] [8]

The cause is typically a bacterial infection and less commonly a fungal infection.[5] Risk factors include valvular heart disease, including rheumatic disease, congenital heart disease, artificial valves, hemodialysis, intravenous drug use, and electronic pacemakers.[9] [10] The bacteria most commonly involved are streptococci or staphylococci.[5] Diagnosis is suspected based on symptoms and supported by blood cultures or ultrasound of the heart.[5] There is also a noninfective form of endocarditis.[5]

The usefulness of antibiotics following dental procedures for prevention is unclear.[11] Some recommend them for people at high risk.[5] Treatment is generally with intravenous antibiotics.[5] The choice of antibiotics is based on the results of blood cultures.[5] Occasionally heart surgery is required.[5] The number of people affected is about 5 per 100,000 per year. Rates, however, vary between regions of the world. Infective endocarditis occurs in males more often than in females.[5] The risk of death among those infected is about 25%.[12] Without treatment, it is almost universally fatal.[5] Improved diagnosis and treatment options have significantly enhanced the life expectancy of patients with infective endocarditis, particularly with congenital heart disease.[13]

Classification

Infective endocarditis is divided into the three categories of acute, subacute, and chronic based on the duration of symptoms.[14] Acute infective endocarditis refers to the presence of signs and symptoms of infective endocarditis that are present for days up to six weeks.[14] If these signs and symptoms persist for more than six weeks but less than three months, this is subacute infective endocarditis.[14] Chronic infective endocarditis refers to the presence of such signs and symptoms when they persist for more than three months.[14]

This classification is now discouraged, because the ascribed associations (in terms of organism and prognosis) were not strong enough to be relied upon clinically. The terms short incubation (meaning less than about six weeks) and long incubation (greater than about six weeks) are preferred.[15]

Culture results

Infective endocarditis may also be classified as culture-positive or culture-negative. By far the most common cause of "culture-negative" endocarditis is prior administration of antibiotics and can occur in up to 31% of cases.[16] [17]

Sometimes microorganisms can take a longer period of time to grow in the culture media, for example Cutibacterium spp.[18] and the HACEK bacteria group. Some organisms are said to be fastidious because they have demanding growth requirements. Some examples include pathogens like Aspergillus species, Brucella species, Coxiella burnetii, Chlamydia species. Due to delay in growth and identification in these cases, patients may be erroneously classified as "culture-negative" endocarditis.[19]

Heart side

Endocarditis can also be classified by the side of the heart affected:

Infection setting

Another form of endocarditis is healthcare-associated endocarditis when the infecting organism is believed to be transmitted in a health care setting like hospital, dialysis unit or a residential nursing home. Nosocomial endocarditis is a form of healthcare associated endocarditis in which the infective organism is acquired during a stay in a hospital and it is usually secondary to presence of intravenous catheters, total parenteral nutrition lines, pacemakers, etc.[21]

Valve type

Finally, the distinction between native-valve endocarditis and prosthetic-valve endocarditis is clinically important. Prosthetic valve endocarditis can be early (within 1 year of surgery) or late (> 1 year following valvular surgery).[22]

Prosthetic valve endocarditis is commonly caused by Staphylococcus epidermidis as it is capable of growing as a biofilm on plastic surfaces.[23] Cutibacterium acnes almost exclusively causes endocarditis on prosthetic heart valves.

Signs and symptoms

Cause

Many microorganisms can cause infective endocarditis. These are generally isolated by blood culture, where the patient's blood is drawn and any growth is noted and identified. The term bacterial endocarditis (BE) commonly is used, reflecting the fact that most cases of IE are due to bacteria; however, infective endocarditis (IE) has become the preferred term.[29]

Bacterial

Staphylococcus aureus is the leading cause of infective endocarditis in most parts of the world and is responsible for about 31% of cases.[14] Staphylococcus aureus is the most common cause of endocarditis in people who use intravenous drugs.[30] Viridans streptococci and Enterococci are the second and third most common organisms responsible for infective endocarditis.[14] Viridans streptococci are a common cause of infective endocarditis in South America. Other Streptococci are also a frequent cause. Infective endocarditis due to Streptococcus bovis occurs more commonly in Europe than in North America.[14] HACEK group of bacteria are also rare causes of infective endocarditis in North America.[31]

The viridans group includes S. oralis, S. mitis, S. sanguis, S. gordonii and S. parasanguis. The primary habitats for these organisms are the oral cavity and upper respiratory tract.[32] These bacteria are present in the normal oral flora and enter the bloodstream due to disruption of tissues in the mouth when dental surgical procedures are performed (tooth extractions) or genitourinary manipulation. Similarly, HACEK organisms are a group of bacteria that live on the dental gums and can be seen with people who inject drugs who contaminate their needles with saliva. Patients may also have a history of poor dental hygiene or pre-existing valvular disease.

Viridans alpha-hemolytic streptococci, that are present in the mouth, are the most frequently isolated microorganisms when the infection is acquired in a community setting. In contrast, Staphylococcus bloodstream infections are frequently acquired in a health care setting where they can enter the bloodstream through procedures that cause breaks in the integrity of skin, such as surgery, catheterization, or during access of long term indwelling catheters or secondary to intravenous injection of recreational drugs.

Enterococcus can enter the bloodstream as a consequence of abnormalities in the gastrointestinal or genitourinary tracts.

Some organisms, when isolated, give valuable clues to the cause, as they tend to be specific.

Multiple case reports of infective endocarditis caused by unusual organisms have been published. Cutibacterium spp., which are normal skin flora, have been responsible for infective endocarditis, preferably in patients with prosthetic heart valves, in rare cases leading to death.[37] Tropheryma whipplei has caused endocarditis without gastrointestinal involvement.[38] Citrobacter koseri was found in an immunocompetent adult.[39] Neisseria bacilliformis was found in a person with a bicuspid aortic valve.[40]

Dental operations

One in eight cases of infective endocarditis is thought to be caused by S. viridans infection associated with dental procedures such as cleaning or tooth extraction. This was thought to be more clinically significant than it is. However, it is important that a dentist or a dental hygienist be told of any heart problems before commencing treatment. Prophylactic antibiotics were regularly administered to patients with certain heart conditions as a precaution, although this practice has changed in the US, with new American Heart Association guidelines released in 2007,[41] and in the UK as of March 2008 due to new NICE guidelines.

Fungal

Fungal endocarditis (FE) is often fatal and one of the most serious forms of infective endocarditis. The types of fungi most seen associated with this disease are:

Candida albicans is found as a spherical or oval budding yeast. It is associated with endocarditis in people who inject drugs, patients with prosthetic valves, and immunocompromised patients. It forms biofilms around thick-walled resting structures like prosthetic heart valves and additionally colonizes and penetrates endothelial walls. C. albicans is responsible for 24-46% of all the cases of FE, and its mortality rate is 46.6–50%.[42]

Other fungi demonstrated to cause endocarditis are Histoplasma capsulatum and Aspergillus. Aspergillus contributes to roughly 25% of FE cases. Endocarditis with Tricosporon asahii has also been reported in a case report.[43]

Risk factors

Risk factors for infective endocarditis are based on the premise that in a healthy individual, bacteremia (bacteria entering the bloodstream) is cleared quickly with no adverse consequences. However, if a heart valve is damaged, the bacteria can attach themselves to the valve, resulting in infective endocarditis. Additionally, in individuals with weakened immune systems, the concentration of bacteria in the blood can reach levels high enough to increase the probability that some will attach to the valve. Some significant risk factors are listed here:[14]

Pathogenesis

Damaged valves and endocardium contribute to the development of infective endocarditis. Specifically, the damaged part of a heart valve forms a local blood clot, a condition known as non-bacterial thrombotic endocarditis (NBTE). The platelet and fibrin deposits that form as part of the blood clotting process allow bacteria to take hold and form vegetations. As previously mentioned, the body has no direct methods of combating valvular vegetations because the valves do not have a dedicated blood supply. This combination of damaged valves, bacterial growth, and lack of a strong immune response results in infective endocarditis.

Damage to the valves and endocardium can be caused by:

The risk factors for infective endocarditis provide a more extensive list of conditions that can damage the heart.

Diagnosis

In general, the Duke criteria should be fulfilled in order to establish the diagnosis of endocarditis.[14] [44] Although the Duke criteria are widely used, they have significant limitations.[14] For example, the sensitivity of the Duke criteria for detecting infective endocarditis decreases when prosthetic heart valves are present.[14]

As the Duke criteria rely heavily on the results of echocardiography, research has addressed when to order an echocardiogram by using signs and symptoms to predict occult endocarditis among people who inject drugs[45] [46] [47] and among non drug-abusing patients.[48] [49] However, this research is over twenty years old and it is possible that changes in the epidemiology of endocarditis and bacteria such as staphylococci make the following estimates incorrect.

The blood tests C reactive protein (CRP) and procalcitonin have not been found to be particularly useful in helping make or rule out the diagnosis.[50]

Ultrasound

Echocardiography is the main type of diagnostic imaging used to establish the diagnosis of infective endocarditis.[14] There are two main types of echocardiography used to assist with the diagnosis of IE: transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE).[14]

The transthoracic echocardiogram has a sensitivity and specificity of approximately 65% and 95% if the echocardiographer believes there is 'probable' or 'almost certain' evidence of endocarditis.[51] [52] However, in endocarditis involving a prosthetic valve, TTE has a sensitivity of approximately 50%, whereas TEE has a sensitivity exceeding 90%. The TEE also has an important diagnostic role when the TTE does not reveal IE but diagnostic suspicion remains high, since TEE is more sensitive for infective endocarditis and is better able to characterize infection-related damage to the heart valves and surrounding tissues.

Guidelines support the initial use of TTE over TEE in people with abnormal blood cultures, a new heart murmur, and suspected infective endocarditis. TEE is the preferred initial form of imaging in people with suspected infective endocarditis who have a moderate to high pretest probability of infective endocarditis, including people with prosthetic heart valves, blood cultures growing Staphylococcus, or have an intracardiac device (such as a pacemaker).

Modified Duke criteria

Established in 1994 by the Duke Endocarditis Service and revised in 2000, the Duke criteria are a collection of major and minor criteria used to establish a diagnosis of infective endocarditis.[44] [53] According to the Duke criteria, diagnosis of infective endocarditis can be definite, possible, or rejected. A diagnosis of infective endocarditis is definite if either the following pathological or clinical criteria are met:

One of these pathological criteria:

One of these combinations of clinical criteria

Diagnosis of infective endocarditis is possible if one of the following combinations of clinical criteria is met:

Major criteria

Positive blood culture with typical IE microorganism, defined as one of the following:

Evidence of endocardial involvement with positive echocardiogram is defined as

Minor criteria

Updated (2023) Modified Duke Criteria for Infective Endocarditis: Infective endocarditis (IE) is a life-threatening condition and the Duke criteria (established in 1994 and revised in 2000) has been fundamental for the diagnosis of the disease. However, the landscape of micro-biology, diagnostics, epidemiology, and treatment for lE has evolved significantly over the years. The 2023 modified Duke criteria address these changes: https://medicalstudyhub.com/updated-2023-modified-duke-criteria-for-infective-endocarditis/

Risk

Among people who do not use intravenous drugs and have a fever in the emergency department, there is a less than 5% chance of occult endocarditis. Mellors in 1987 found no cases of endocarditis nor of staphylococcal bacteremia among 135 febrile patients in the emergency room.[49] The upper confidence interval for 0% of 135 is 5%, so for statistical reasons alone, there is up to a 5% chance of endocarditis among these patients. In contrast, Leibovici found that among 113 non-selected adults admitted to the hospital because of fever there were two cases (1.8% with 95%CI: 0% to 7%) of endocarditis.[48]

Among people who do use intravenous drugs and have a fever in the emergency department, there is about a 10% to 15% prevalence of endocarditis. This estimate is not substantially changed by whether the doctor believes the patient has a trivial explanation for their fever.[47] Weisse found that 13% of 121 patients had endocarditis.[45] Marantz also found a prevalence of endocarditis of 13% among such patients in the emergency department with fever.[47] Samet found a 6% incidence among 283 such patients, but after excluding patients with initially apparent major illness to explain the fever (including 11 cases of manifest endocarditis), there was a 7% prevalence of endocarditis.[46] During the Opioid epidemic in the United States, hospitals observed an increase in stroke associated with infective endocarditis.[54]

Among people with staphylococcal bacteremia (SAB), one study found a 29% prevalence of endocarditis in community-acquired SAB versus 5% in nosocomial SAB.[55] However, only 2% of strains were resistant to methicillin and so these numbers may be low in areas of higher resistance.

Prevention

Not all people with heart disease require antibiotics to prevent infective endocarditis. Heart diseases have been classified into high, medium and low risk of developing IE. Those falling into high risk category require IE prophylaxis before endoscopies and urinary tract procedures.Diseases listed under high risk include:[56]

Following are the antibiotic regimens recommended by the American Heart Association for antibiotic prophylaxis:[41]

Oral amoxicillin one hour before the procedure

Intravenous or intramuscular ampicillin one hour before the procedure

In patients allergic to penicillins

Azithromycin or clarithromycin orally one hour before the procedure

Cephalexin orally one hour before the procedure

Clindamycin orally one hour before the procedure

In the UK, NICE clinical guidelines no longer advise prophylaxis because there is no clinical evidence that it reduces the incidence of IE and there are negative effects (e.g. allergy and increased bacterial resistance) of taking antibiotics that may outweigh the benefits.[57]

Antibiotics were historically commonly recommended to prevent IE in those with heart problems undergoing dental procedures (known as dental antibiotic prophylaxis). There is, however, insufficient evidence to support whether antibiotics are effective or ineffective at preventing IE when given prior to a dental procedures in people at high risk.[58] They are less commonly recommended for this procedure.[59]

In some countries e.g. the US, high risk patients may be given prophylactic antibiotics such as penicillin or clindamycin for penicillin-allergic people prior to dental procedures. Prophylactics should be bactericidal rather than bacteriostatic. Such measures are not taken in certain countries e.g. Scotland due to the fear of antibiotic resistance.[60] Because bacteria are the most common cause of infective endocarditis, antibiotics such as penicillin and amoxicillin (for beta lactamase-producing bacteria) are used in prophylaxis.

Treatment

High-dose antibiotics are the cornerstone of treatment for infective endocarditis. These antibiotics are administered by the intravenous (IV) route to maximize diffusion of antibiotic molecules into vegetation(s) from the blood filling the chambers of the heart. This is necessary because neither the heart valves nor the vegetations adhering to them are supplied by blood vessels. Antibiotics are typically continued for two to six weeks depending on the characteristics of the infection and the causative microorganisms. Antibiotic treatment lowers the risk of embolic complications in people with infective endocarditis.[14]

In acute endocarditis, due to the fulminant inflammation, empirical antibiotic therapy is started immediately after the blood has been drawn for culture to clarify the bacterial organisms responsible for the infection. This usually includes vancomycin and ceftriaxone IV infusions until the infecting organism is identified and the susceptibility report with the minimum inhibitory concentration becomes available. Once this information is available, this allows the supervising healthcare professional to modify the antimicrobial therapy to target the specific infecting microorganism. The routine use of gentamicin to treat endocarditis has fallen out of favor due to the lack of evidence to support its use (except in infections caused by Enterococcus and nutritionally variant streptococci) and the high rate of complications.[61] In cases of subacute endocarditis, where the person's hemodynamic status is usually stable, antibiotic treatment can be delayed until the causative microorganism can be identified.

Viridans group streptococci and Streptococcus bovis are usually highly susceptible to penicillin and can be treated with penicillin or ceftriaxone.[62] Relatively resistant strains of viridans group streptococci and Streptococcus bovis are treated with penicillin or ceftriaxone along with a shorter two-week course of an aminoglycoside during the initial phase of treatment.[62] Highly penicillin-resistant strains of viridans group streptococci, nutritionally variant streptococci like Granulicatella sp., Gemella sp., Abiotrophia defectiva,[63] and Enterococci are usually treated with a combination therapy consisting of penicillin and an aminoglycoside for the entire duration of 4–6 weeks.[62]

Some people may be treated with a relatively shorter course of treatment[62] (two weeks) with benzyl penicillin IV if infection is caused by viridans group streptococci or Streptococcus bovis as long as the following conditions are met:

Additionally, oxacillin-susceptible Staphylococcus aureus native valve endocarditis of the right side can also be treated with a short 2-week course of a beta-lactam antibiotic such as nafcillin with or without aminoglycosides.

The main indication for surgical treatment is regurgitation or stenosis. In active infective endocarditis, the surgery should remove enough leaflet tissue to ensure eradication of the infectious process.[64] Subsequent valve repair can be performed in limited disease.[64] Replacement of the valve with a mechanical or bioprosthetic artificial heart valve is necessary in certain situations:[65]

The guidelines were recently updated by both the American College of Cardiology and the European Society of Cardiology. There was a recent meta-analysis published that showed surgical intervention at seven days or less is associated with lower mortality.[66]

Prognosis

Infective endocarditis is associated with 18% in-hospital mortality.[31] However, adult patients with congenital heart disease can have relatively lower mortality down to 5% due to younger age, right-sided endocarditis and management by multidisciplinary teams. As many as 50% of people with infective endocarditis may experience embolic complications.[14]

Epidemiology

In developed countries, the annual incidence of infective endocarditis is 3 to 9 cases per 100,000 persons.[67] Infective endocarditis occurs more often in men than in women.[14] There is an increased incidence of infective endocarditis in persons 65 years of age and older, which is probably because people in this age group have a larger number of risk factors for infective endocarditis. In recent years, over one-third of infective endocarditis cases in the United States was healthcare-associated. Another trend observed in developed countries is that chronic rheumatic heart disease accounts for less than 10% of cases. Although a history of valve disease has a significant association with infective endocarditis, 50% of all cases develop in people with no known history of valvular disease.

History

Lazare Riviére first described infective endocarditis affecting the aortic valve in 1616.[14] In 1806, Jean-Nicolas Corvisart coined the term vegetation to describe collections of debris found on a mitral valve affected by infective endocarditis.[14] The British physician Joseph Hodgson was the first to describe the embolic complications of infective endocarditis in 1815.[14] It was not until 1878 that Theodor Klebs first suggested that infective endocarditis had a microbial infectious origin.[14] In 1909, William Osler noted that heart valves that experienced degeneration and were sclerotic or poorly functioning had a higher risk of being affected.[14] Later, in 1924, Emanuel Libman and Benjamin Sacks described cases of vegetative endocarditis that lacked a clear microbial origin and were often associated with the autoimmune condition systemic lupus erythematosus.[14] In 1944, physicians reported on the first successful use of penicillin to treat a case of infective endocarditis.[14]

Notes and References

  1. News: Endocarditis . June 4, 2022 . Mayo Clinic .
  2. Web site: Cleveland Clinic . Endocarditis . 2022-06-09.
  3. Verzelloni Sef . A . Jaggar . SI . Trkulja . V . Alonso-Gonzalez . R . Sef . D . Turina . MI . Factors associated with long-term outcomes in adult congenital heart disease patients with infective endocarditis: A 16-year tertiary single-centre experience. . European Journal of Cardio-Thoracic Surgery . 22 March 2023 . 63 . 5 . 10.1093/ejcts/ezad105 . 36946284.
  4. Habib . G . Lancellotti . P . Antunes . MJ . Bongiorni . MG . Casalta . JP . Del Zotti . F . Dulgheru . R . El Khoury . G . Erba . PA . Iung . B . Miro . JM . Mulder . BJ . Plonska-Gosciniak . E . Price . S . Roos-Hesselink . J . Snygg-Martin . U . Thuny . F . Tornos Mas . P . Vilacosta . I . Zamorano . JL . ESC Scientific Document . Group . 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). . European Heart Journal . 21 November 2015 . 36 . 44 . 3075–3128 . 10.1093/eurheartj/ehv319 . 26320109. free .
  5. News: Infective Endocarditis – Cardiovascular Disorders. Merck Manuals Professional Edition. 11 December 2017. en-CA. September 2017.
  6. Kumar M, Anstadt EJ, Lopetegui Lia N, Siddiqi MH . Streptococcus viridans Endocarditis Affecting All Four Valves . Cureus . 11 . 5 . e4635 . May 2019 . 31312561 . 6623990 . 10.7759/cureus.4635 . free .
  7. Njuguna B, Gardner A, Karwa R, Delahaye F . Infective Endocarditis in Low- and Middle-Income Countries . Cardiology Clinics . 35 . 1 . 153–163 . February 2017 . 27886786 . 10.1016/j.ccl.2016.08.011 . free . 1805/14046 .
  8. Merkler . Alexander E. . Chu . Stacy Y. . Lerario . Michael P. . Navi . Babak B. . Kamel . Hooman . 2015-08-11 . Temporal relationship between infective endocarditis and stroke . Neurology . 85 . 6 . 512–516 . 10.1212/WNL.0000000000001835 . 1526-632X . 4540247 . 26163428.
  9. Habib . G . Lancellotti . P . Antunes . MJ . Bongiorni . MG . Casalta . JP . Del Zotti . F . Dulgheru . R . El Khoury . G . Erba . PA . Iung . B . Miro . JM . Mulder . BJ . Plonska-Gosciniak . E . Price . S . Roos-Hesselink . J . Snygg-Martin . U . Thuny . F . Tornos Mas . P . Vilacosta . I . Zamorano . JL . ESC Scientific Document . Group . 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). . European Heart Journal . 21 November 2015 . 36 . 44 . 3075–3128 . 10.1093/eurheartj/ehv319 . 26320109. free .
  10. Verzelloni Sef . A . Jaggar . SI . Trkulja . V . Alonso-Gonzalez . R . Sef . D . Turina . MI . Factors associated with long-term outcomes in adult congenital heart disease patients with infective endocarditis: A 16-year tertiary single-centre experience. . European Journal of Cardio-Thoracic Surgery . 22 March 2023 . 63 . 5 . 10.1093/ejcts/ezad105 . 36946284.
  11. Cahill TJ, Harrison JL, Jewell P, Onakpoya I, Chambers JB, Dayer M, Lockhart P, Roberts N, Shanson D, Thornhill M, Heneghan CJ, Prendergast BD . 25918810 . Antibiotic prophylaxis for infective endocarditis: a systematic review and meta-analysis . Heart . 103 . 12 . 937–944 . June 2017 . 28213367 . 10.1136/heartjnl-2015-309102 .
  12. Ambrosioni J, Hernandez-Meneses M, Téllez A, Pericàs J, Falces C, Tolosana JM, Vidal B, Almela M, Quintana E, Llopis J, Moreno A, Miro JM . 24935834 . The Changing Epidemiology of Infective Endocarditis in the Twenty-First Century . Current Infectious Disease Reports . 19 . 5 . 21 . May 2017 . 28401448 . 10.1007/s11908-017-0574-9 .
  13. Verzelloni Sef . A . Jaggar . SI . Trkulja . V . Alonso-Gonzalez . R . Sef . D . Turina . MI . Factors associated with long-term outcomes in adult congenital heart disease patients with infective endocarditis: A 16-year tertiary single-centre experience. . European Journal of Cardio-Thoracic Surgery . 22 March 2023 . 63 . 5 . 10.1093/ejcts/ezad105 . 36946284.
  14. Hubers SA, DeSimone DC, Gersh BJ, Anavekar NS . Infective Endocarditis: A Contemporary Review . Mayo Clinic Proceedings . 95 . 5 . 982–997 . May 2020 . 32299668 . 10.1016/j.mayocp.2019.12.008 . free .
  15. Morris AM . 10450799 . How best to deal with endocarditis . Current Infectious Disease Reports . 8 . 1 . 14–22 . January 2006 . 16448596 . 10.1007/s11908-006-0030-8 .
  16. Web site: Endocarditis. The Lecturio Medical Concept Library . 18 July 2021.
  17. Habib . G . Lancellotti . P . Antunes . MJ . Bongiorni . MG . Casalta . JP . Del Zotti . F . Dulgheru . R . El Khoury . G . Erba . PA . Iung . B . Miro . JM . Mulder . BJ . Plonska-Gosciniak . E . Price . S . Roos-Hesselink . J . Snygg-Martin . U . Thuny . F . Tornos Mas . P . Vilacosta . I . Zamorano . JL . ESC Scientific Document . Group . 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). . European Heart Journal . 21 November 2015 . 36 . 44 . 3075–3128 . 10.1093/eurheartj/ehv319 . 26320109. free .
  18. Sohail MR, Gray AL, Baddour LM, Tleyjeh IM, Virk A . Infective endocarditis due to Propionibacterium species . Clinical Microbiology and Infection . 15 . 4 . 387–94 . April 2009 . 19260876 . 10.1111/j.1469-0691.2009.02703.x . free .
  19. Holland T, Baddour L, Bayer A, Hoen B, Miro J, Fowler V . 1 September 2016 . Infective endocarditis. Nature Reviews Disease Primers. 2. 16059 . 10.1038/nrdp.2016.59. 27582414. 5240923.
  20. Habib . G . Lancellotti . P . Antunes . MJ . Bongiorni . MG . Casalta . JP . Del Zotti . F . Dulgheru . R . El Khoury . G . Erba . PA . Iung . B . Miro . JM . Mulder . BJ . Plonska-Gosciniak . E . Price . S . Roos-Hesselink . J . Snygg-Martin . U . Thuny . F . Tornos Mas . P . Vilacosta . I . Zamorano . JL . ESC Scientific Document . Group . 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). . European Heart Journal . 21 November 2015 . 36 . 44 . 3075–3128 . 10.1093/eurheartj/ehv319 . 26320109. free .
  21. Book: Kasper DL, Brunwald E, Fauci AS, Hauser S, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine . McGraw-Hill . 2005 . 731–40 . 978-0-07-139140-5 . 54501403. Harrison's Principles of Internal Medicine .
  22. Habib . G . Lancellotti . P . Antunes . MJ . Bongiorni . MG . Casalta . JP . Del Zotti . F . Dulgheru . R . El Khoury . G . Erba . PA . Iung . B . Miro . JM . Mulder . BJ . Plonska-Gosciniak . E . Price . S . Roos-Hesselink . J . Snygg-Martin . U . Thuny . F . Tornos Mas . P . Vilacosta . I . Zamorano . JL . ESC Scientific Document . Group . 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). . European Heart Journal . 21 November 2015 . 36 . 44 . 3075–3128 . 10.1093/eurheartj/ehv319 . 26320109. free .
  23. Otto M . Staphylococcus epidermidis--the 'accidental' pathogen . Nature Reviews. Microbiology . 7 . 8 . 555–67 . August 2009 . 19609257 . 2807625 . 10.1038/nrmicro2182 .
  24. Book: Amal M, Deepi G, Jeffrey W, Joshua B, DeAngelis M, Peter D, Gus MG, Richard H, David K, Anita L . 6 . Emergency medicine: avoiding the pitfalls and improving the outcomes . Blackwell/BMJ Books . 2007 . 63 . 978-1-4051-4166-6 .
  25. Misin . Andrea . Bella . Stefano Di . Priolo . Luigi . Luzzati . Roberto . 2017 . Image of the month: 'Diagnostic hands': Janeway lesions . Clinical Medicine . en . 17 . 4 . 373–374 . 10.7861/clinmedicine.17-4-373 . 1470-2118 . 6297653 . 28765422.
  26. Book: Ferro JM, Fonseca AC . Infective endocarditis . 119 . 75–91 . 2014 . 24365290 . 10.1016/B978-0-7020-4086-3.00007-2 . Handbook of Clinical Neurology . 9780702040863 . Neurologic Aspects of Systemic Disease Part I .
  27. Book: Mitchell RS, Kumar V, Robbins SL, Abbas AK, Fausto N . Robbins Basic Pathology . Saunders/Elsevier . 8th . 2007 . 406–8 . 978-1-4160-2973-1.
  28. Web site: Heart Valves and Infective Endocarditis. American Heart Association . 18 July 2021.
  29. Habib . G . Lancellotti . P . Antunes . MJ . Bongiorni . MG . Casalta . JP . Del Zotti . F . Dulgheru . R . El Khoury . G . Erba . PA . Iung . B . Miro . JM . Mulder . BJ . Plonska-Gosciniak . E . Price . S . Roos-Hesselink . J . Snygg-Martin . U . Thuny . F . Tornos Mas . P . Vilacosta . I . Zamorano . JL . ESC Scientific Document . Group . 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). . European Heart Journal . 21 November 2015 . 36 . 44 . 3075–3128 . 10.1093/eurheartj/ehv319 . 26320109. free .
  30. Book: Chan KL, Embil JM . Endocarditis: Diagnosis and Management . 2016 . Springer . 978-3-319-27784-4 . 39 . en.
  31. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH . Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study . Archives of Internal Medicine . 169 . 5 . 463–73 . March 2009 . 19273776 . 3625651 . 10.1001/archinternmed.2008.603 .
  32. Book: Essentials of microbiology for dental students. Bagg J . 2006. Oxford University Press. 9780198564898. 2nd. Oxford. 61756542.
  33. Web site: Pseudomonas aeruginosa . August 2001 . Topics in Infectious Diseases Newsletter . July 24, 2008 . dead . https://web.archive.org/web/20080724235537/http://wordnet.com.au/Products/topics_in_infectious_diseases_Aug01.htm .
  34. Gold JS, Bayar S, Salem RR . Association of Streptococcus bovis bacteremia with colonic neoplasia and extracolonic malignancy . Archives of Surgery . 139 . 7 . 760–5 . July 2004 . 15249410 . 10.1001/archsurg.139.7.760 . free .
  35. Chew SS, Lubowski DZ . Clostridium septicum and malignancy . ANZ Journal of Surgery . 71 . 11 . 647–9 . November 2001 . 11736823 . 10.1046/j.1445-1433.2001.02231.x . 7571197 .
  36. Lamas CC, Eykyn SJ . Blood culture negative endocarditis: analysis of 63 cases presenting over 25 years . Heart . 89 . 3 . 258–62 . March 2003 . 12591823 . 1767579 . 10.1136/heart.89.3.258 .
  37. Clayton JJ, Baig W, Reynolds GW, Sandoe JA . Endocarditis caused by Propionibacterium species: a report of three cases and a review of clinical features and diagnostic difficulties . Journal of Medical Microbiology . 55 . Pt 8 . 981–987 . August 2006 . 16849716 . 10.1099/jmm.0.46613-0 . free .
  38. Dreier J, Szabados F, von Herbay A, Kröger T, Kleesiek K . Tropheryma whipplei Infection of an acellular porcine heart valve bioprosthesis in a patient who did not have intestinal Whipple's disease . Journal of Clinical Microbiology . 42 . 10 . 4487–93 . October 2004 . 15472298 . 522317 . 10.1128/JCM.42.10.4487-4493.2004 .
  39. Dzeing-Ella A, Szwebel TA, Loubinoux J, Coignard S, Bouvet A, Le Jeunne C, Aslangul E . Infective endocarditis due to Citrobacter koseri in an immunocompetent adult . Journal of Clinical Microbiology . 47 . 12 . 4185–6 . December 2009 . 19812281 . 2786675 . 10.1128/JCM.00957-09 .
  40. Masliah-Planchon J, Breton G, Jarlier V, Simon A, Benveniste O, Herson S, Drieux L . Endocarditis due to Neisseria bacilliformis in a patient with a bicuspid aortic valve . Journal of Clinical Microbiology . 47 . 6 . 1973–5 . June 2009 . 19386832 . 2691068 . 10.1128/JCM.00026-09 .
  41. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT . 6 . Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group . Circulation . 116 . 15 . 1736–54 . October 2007 . 17446442 . 10.1161/CIRCULATIONAHA.106.183095 . free .
  42. Yuan SM . Fungal Endocarditis . Brazilian Journal of Cardiovascular Surgery . 31 . 3 . 252–255 . 2016 . 27737409 . 5062704 . 10.5935/1678-9741.20160026 .
  43. Izumi K, Hisata Y, Hazama S . A rare case of infective endocarditis complicated by Trichosporon asahii fungemia treated by surgery . Annals of Thoracic and Cardiovascular Surgery . 15 . 5 . 350–3 . October 2009 . 19901894 .
  44. Durack DT, Lukes AS, Bright DK . New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service . The American Journal of Medicine . 96 . 3 . 200–9 . March 1994 . 8154507 . 10.1016/0002-9343(94)90143-0 .
  45. Weisse AB, Heller DR, Schimenti RJ, Montgomery RL, Kapila R . The febrile parenteral drug user: a prospective study in 121 patients . The American Journal of Medicine . 94 . 3 . 274–80 . March 1993 . 8452151 . 10.1016/0002-9343(93)90059-X .
  46. Samet JH, Shevitz A, Fowle J, Singer DE . Hospitalization decision in febrile intravenous drug users . The American Journal of Medicine . 89 . 1 . 53–7 . July 1990 . 2368794 . 10.1016/0002-9343(90)90098-X . free .
  47. Marantz PR, Linzer M, Feiner CJ, Feinstein SA, Kozin AM, Friedland GH . Inability to predict diagnosis in febrile intravenous drug abusers . Annals of Internal Medicine . 106 . 6 . 823–8 . June 1987 . 3579068 . 10.7326/0003-4819-106-6-823 .
  48. Leibovici L, Cohen O, Wysenbeek AJ . Occult bacterial infection in adults with unexplained fever. Validation of a diagnostic index . Archives of Internal Medicine . 150 . 6 . 1270–2 . June 1990 . 2353860 . 10.1001/archinte.150.6.1270 .
  49. Mellors JW, Horwitz RI, Harvey MR, Horwitz SM . A simple index to identify occult bacterial infection in adults with acute unexplained fever . Archives of Internal Medicine . 147 . 4 . 666–71 . April 1987 . 3827454 . 10.1001/archinte.147.4.666 .
  50. Yu CW, Juan LI, Hsu SC, Chen CK, Wu CW, Lee CC, Wu JY . Role of procalcitonin in the diagnosis of infective endocarditis: a meta-analysis . The American Journal of Emergency Medicine . 31 . 6 . 935–41 . June 2013 . 23601504 . 10.1016/j.ajem.2013.03.008 .
  51. Shively BK, Gurule FT, Roldan CA, Leggett JH, Schiller NB . Diagnostic value of transesophageal compared with transthoracic echocardiography in infective endocarditis . Journal of the American College of Cardiology . 18 . 2 . 391–7 . August 1991 . 1856406 . 10.1016/0735-1097(91)90591-V . free .
  52. Erbel R, Rohmann S, Drexler M, Mohr-Kahaly S, Gerharz CD, Iversen S, Oelert H, Meyer J . Improved diagnostic value of echocardiography in patients with infective endocarditis by transoesophageal approach. A prospective study . European Heart Journal . 9 . 1 . 43–53 . January 1988 . 3345769 . 10.1093/oxfordjournals.eurheartj.a062389.
  53. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, Bashore T, Corey GR . Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis . Clinical Infectious Diseases . 30 . 4 . 633–8 . April 2000 . 10770721 . 10.1086/313753 . free .
  54. Salehi Omran . Setareh . Chatterjee . Abhinaba . Chen . Monica L. . Lerario . Michael P. . Merkler . Alexander E. . Kamel . Hooman . March 2019 . National Trends in Hospitalizations for Stroke Associated With Infective Endocarditis and Opioid Use Between 1993 and 2015 . Stroke . en . 50 . 3 . 577–582 . 10.1161/STROKEAHA.118.024436 . 30699043 . 6396300 . 0039-2499.
  55. Kaech C, Elzi L, Sendi P, Frei R, Laifer G, Bassetti S, Fluckiger U . Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre . Clinical Microbiology and Infection . 12 . 4 . 345–52 . April 2006 . 16524411 . 10.1111/j.1469-0691.2005.01359.x . free .
  56. Habib . G . Lancellotti . P . Antunes . MJ . Bongiorni . MG . Casalta . JP . Del Zotti . F . Dulgheru . R . El Khoury . G . Erba . PA . Iung . B . Miro . JM . Mulder . BJ . Plonska-Gosciniak . E . Price . S . Roos-Hesselink . J . Snygg-Martin . U . Thuny . F . Tornos Mas . P . Vilacosta . I . Zamorano . JL . ESC Scientific Document . Group . 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). . European Heart Journal . 21 November 2015 . 36 . 44 . 3075–3128 . 10.1093/eurheartj/ehv319 . 26320109. free .
  57. Web site: Prophylaxis against infective endocarditis: Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures . National Institute for Health Care and Excellence (UK) . NICE Clinical Guidelines . March 2008 . 2013-04-30 . dead . https://web.archive.org/web/20130126164822/http://publications.nice.org.uk/prophylaxis-against-infective-endocarditis-cg64 . 2013-01-26 .
  58. Rutherford SJ, Glenny AM, Roberts G, Hooper L, Worthington HV . Antibiotic prophylaxis for preventing bacterial endocarditis following dental procedures . The Cochrane Database of Systematic Reviews . 2022 . 5 . CD003813 . May 2022 . 35536541 . 9088886 . 10.1002/14651858.CD003813.pub5 .
  59. 2008. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures.. National Institute for Health and Care Excellence (NICE).
  60. News: Drug Prescribing . SDCEP. 2018-01-25. en-US.
  61. Cosgrove SE, Vigliani GA, Fowler VG, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW . Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic . Clinical Infectious Diseases . 48 . 6 . 713–21 . March 2009 . 19207079 . 10.1086/597031 . free .
  62. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA . 6 . Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America . Circulation . 111 . 23 . e394–434 . June 2005 . 15956145 . 10.1161/CIRCULATIONAHA.105.165564 . free .
  63. Kalavakunta JK, Davenport DS, Tokala H, King A, Khagny M, Gupta V . Destructive Abiotrophia defectiva endocarditis . The Journal of Heart Valve Disease . 20 . 1 . 111–2 . January 2011 . 21404910 .
  64. Rostagno C, Carone E, Stefàno PL. Role of mitral valve repair in active infective endocarditis: long term results. . J Cardiothorac Surg . 2017 . 12 . 1 . 29 . 28521809 . 10.1186/s13019-017-0604-6 . 5437579 . free .
  65. Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, Nishimura RA, Carabello BA, Faxon DP, Freed MD, Lytle BW, O'Gara PT, O'Rourke RA, Shah PM . 6 . 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons . Journal of the American College of Cardiology . 52 . 13 . e1–142 . September 2008 . 18848134 . 10.1016/j.jacc.2008.05.007 . free .
  66. 26869640 . 10.1136/heartjnl-2015-308589 . 102 . Early versus late surgical intervention or medical management for infective endocarditis: a systematic review and meta-analysis . 2016 . Anantha Narayanan M, Mahfood Haddad T, Kalil AC, Kanmanthareddy A, Suri RM, Mansour G, Destache CJ, Baskaran J, Mooss AN, Wichman T, Morrow L, Vivekanandan R . 12007082 . Heart . 12 . 950–7.
  67. Hoen B, Duval X . Clinical practice. Infective endocarditis . The New England Journal of Medicine . 368 . 15 . 1425–33 . April 2013 . 23574121 . 10.1056/NEJMcp1206782 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Infective endocarditis".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.